DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX)

Today's Latest Price: $1.57 USD

0.04 (2.61%)

Updated Apr 8 8:00pm

Add DRRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DRRX Stock Summary

  • Price to trailing twelve month operating cash flow for DRRX is currently 24.7, higher than 89.2% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 9.27, Durect Corp has a higher such ratio than 91.31% of stocks in our set.
  • Revenue growth over the past 12 months for Durect Corp comes in at 59.25%, a number that bests 90.7% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Durect Corp are ADXS, TNAV, TROV, NOVN, and AKBA.
  • DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.
DRRX Daily Price Range
DRRX 52-Week Price Range

DRRX Stock Price Chart More Charts


DRRX Price/Volume Stats

Current price $1.57 52-week high $3.95
Prev. close $1.53 52-week low $0.50
Day low $1.46 Volume 416,100
Day high $1.57 Avg. volume 1,501,752
50-day MA $1.69 Dividend yield N/A
200-day MA $1.74 Market Cap 307.44M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.

DRRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$1.57$315.5220522%

Below please find a table outlining a discounted cash flow forecast for DRRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Durect Corp ranked in the 98th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 20623.33%; returns of such proportions should be viewed with some skepticism, though. In terms of the factors that were most noteworthy in this DCF analysis for DRRX, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is -7.23; that's higher than merely 9.56% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet reveals debt to be 9% of the company's capital (with equity being the remaining amount). Approximately merely 19.4% of US stocks with free cash flow have a lower reliance on debt in their capital structure.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%20118%
1%20320%
2%20522%
3%20724%
4%20927%
5%21129%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DRRX, try NVCR, FVE, VRTX, QHC, and ASRT.


DRRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

DRRX Price Returns

1-mo -16.49%
3-mo -41.42%
6-mo -7.65%
1-year 131.43%
3-year 60.20%
5-year -20.71%
YTD -58.68%
2019 691.67%
2018 -47.83%
2017 -31.34%
2016 -39.37%
2015 179.75%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7664 seconds.